Xeris Biopharma Holdings Inc

For the period ended Dec 31, 2024. Filed Mar 6, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 6, 2025

XERS$15.86+4.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Financial Statements Consolidated Balance Sheets as of December 31, 202 and December 31,

Consolidated Balance Sheets

(in thousands, except share and par value)

	December 31, 2024	December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$71,621	$67,449
Short-term investments	—	5,002
Trade accounts receivable, net	40,415	39,197
Inventory, net	48,175	38,838
Prepaid expenses and other current assets	7,451	5,778
Total current assets	167,662	156,264
Property and equipment, net	5,562	5,971
Operating lease right-of-use assets	22,649	23,204
Goodwill	22,859	22,859
Intangible assets, net	98,921	109,764
Other assets	5,407	4,540
Total assets	$323,060	$322,602
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$2,290	$11,565
Current portion of long-term debt	15,102	—
Current operating lease liabilities	6,080	3,495
Other accrued liabilities	27,716	23,510
Accrued trade discounts and rebates	29,084	22,149
Accrued returns reserve	19,082	14,198
Current portion of contingent value rights	—	19,109
Other current liabilities	1,089	1,167
Total current liabilities	100,443	95,193
Long-term debt, net of current portion and unamortized debt issuance costs	217,006	190,932
Non-current operating lease liabilities	33,259	34,764
Non-current contingent value rights	—	1,379
Deferred tax liabilities	—	2,268
Other liabilities	1,967	4,848
Total liabilities	352,675	329,384
Commitments and contingencies (Note 15)
Stockholders' equity (deficit):
Preferred stock—par value $0.0001, 25,000,000 shares and 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	—	—
Common stock—par value $0.0001, 350,000,000 shares and 350,000,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; 149,429,410 and 138,130,715 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	15	14
Additional paid in capital	642,256	610,254
Accumulated deficit	(671,861)	(617,025)
Accumulated other comprehensive loss	(25)	(25)
Total stockholders' equity (deficit)	(29,615)	(6,782)
Total liabilities and stockholders' equity (deficit)	$323,060	$322,602

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.